First approved in 2000 for termination of pregnancies of ≤49 days' gestation, the indication for the oral antiprogestin mifepristone ( Mifeprex , and generics) was expanded in 2016 to include pregnancies of…
Med Lett Drugs Ther. 2023 Feb 20; 65(1670):31 doi:10.58347/tml.2023.1670c
First approved in 2000 for termination of pregnancies of ≤49 days' gestation, the indication for the oral antiprogestin mifepristone ( Mifeprex , and generics) was expanded in 2016 to include pregnancies of up to 10 weeks' gestation. A single 200-mg oral dose of mifepristone followed 24-48 hours later by a single 800-mcg buccal dose of the prostaglandin analog misoprostol terminates early intrauterine pregnancies in about 95% of women.
The FDA has removed the requirement that mifepristone ( Mifeprex , and generics), a progestin receptor antagonist approved for use in a regimen with the prostaglandin E1 analog misoprostol ( Cytotec , and…
Med Lett Drugs Ther. 2022 Jan 24; 64(1642):11
The FDA has removed the requirement that mifepristone ( Mifeprex , and generics), a progestin receptor antagonist approved for use in a regimen with the prostaglandin E1 analog misoprostol ( Cytotec , and generics) for medical termination of pregnancy, must be dispensed in person to the patient.
The FDA has approved osilodrostat ( Isturisa – Recordati), a cortisol synthesis inhibitor, for oral treatment of adults with Cushing's disease when surgical resection of the pituitary adenoma is not an…
Med Lett Drugs Ther. 2021 Feb 8; 63(1617):21-3
The FDA has approved osilodrostat ( Isturisa – Recordati), a cortisol synthesis inhibitor, for oral treatment of adults with Cushing's disease when surgical resection of the pituitary adenoma is not an option or has not been curative. Osilodrostat is the first cortisol synthesis inhibitor to be approved in the US for this indication. Other oral steroidogenesis inhibitors such as ketoconazole and metyrapone have been used off-label for this indication for many years.
The FDA has approved several significant changes in the labeling of mifepristone ( Mifeprex – Danco), an oral antiprogestin that has been used in the US for more than 15 years for termination of intrauterine…
Med Lett Drugs Ther. 2016 Apr 25; 58(1493):55-6
The FDA has approved several significant changes in the labeling of mifepristone ( Mifeprex – Danco), an oral antiprogestin that has been used in the US for more than 15 years for termination of intrauterine pregnancy. It has generally been used with the prostaglandin analog misoprostol ( Cytotec , and generics).
Misoprostol ( Cytotec , and generics), a prostaglandin E 1 analog FDA-approved for prevention of NSAID-induced gastric ulcers and, when taken with mifepristone (Mifeprex) , for termination of early…
Med Lett Drugs Ther. 2013 Mar 4; 55(1411):19-20
Misoprostol ( Cytotec , and generics), a prostaglandin E 1 analog FDA-approved for prevention of NSAID-induced gastric ulcers and, when taken with mifepristone (Mifeprex) , for termination of early intrauterine pregnancy, has also been used off-label for years for medical management of first-trimester spontaneous abortion (miscarriage).
The FDA has approved the antiprogestin mifepristone ( Korlym – Corcept Therapeutics) for control of hyperglycemia secondary to hypercortisolism in adults with endogenous Cushing’s syndrome who have type 2…
Med Lett Drugs Ther. 2012 Jun 11; 54(1392):46-7
The FDA has approved the antiprogestin mifepristone ( Korlym – Corcept Therapeutics) for control of hyperglycemia secondary to hypercortisolism in adults with endogenous Cushing’s syndrome who have type 2 diabetes/ glucose intolerance and have not responded to, or are not candidates for, surgery. Formerly known as RU 486, mifepristone is also available in a lower strength as Mifeprex for use in terminating an early intrauterine pregnancy.
Recent articles in the press have suggested that in early pregnancy, an intramuscular (IM) injection of methotrexate (Folex, and others), a folic acid antagonist, and oral or vaginal administration of…
Med Lett Drugs Ther. 1996 Apr 26; 38(973):39-40
Recent articles in the press have suggested that in early pregnancy, an intramuscular (IM) injection of methotrexate (Folex, and others), a folic acid antagonist, and oral or vaginal administration of misoprostol (Cytotec), a prostaglandin, offers a medical alternative to a surgically induced abortion. Methotrexate is approved by the US Food and Drug Administration for use in rheumatoid arthritis, psoriasis and various types of cancer, including choriocarcinoma, and has also been used to terminate ectopic pregnancies. Misoprostol is approved for prevention of gastric ulcers induced by nonsteroidal anti-inflammatory drugs (NSAIDs). In France, the United Kingdom and Sweden, misoprostol or another prostaglandin is used with mifepristone (RU486) to induce abortions in early pregnancy (Medical Letter, 32:112, 1990).